Diabetes Type 2

Donna Ryan, MD, discusses the most significant clinical trials published this year in the field of obesity medicine.

ACG 2024: New study results indicate GLP-1 RAs have a potentially protective role to play in combating EO-CRC, the incidence of which is notably rising worldwide.

In a post hoc analysis of the SCORED trial, investigators observed positive renal protection with sotagliflozin across a spectrum of baseline kidney function and glycemic control.

Novo Nordisk plans to file for regulatory approval this year of an expanded label for oral semaglutide, with an indication for reduction of MACE in high-risk adults with T2D.

Find details on challenges primary care clinicians face in treating older adults with T2D and an expert discussion on navigating treatments to delay T1D.

Find details on advances in the management of type 1 diabetes, utilization of CGM in primary care settings, and optimizing T2D management in older persons.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Across two clinical trials in the QWINT program, once-wekly efsitora showed comparable A1C reduction to frequently used daily insulins.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Type 2 diabetes and prediabetes were associated with accelerated brain aging, particularly among men and persons with poor cardiometabolic health, according to new research.

The Omnipod 5 is now the first automated insulin delivery system available for both T1D and T2D in the US.

Results of a global analysis of over 30 million cases showed significantly higher odds for suicidal ideation among adults who received semaglutide vs other medications.

Your daily dose of the clinical news you may have missed.

Results of the 3-year SURMOUNT-1 study reflect the longest trial to date of tirzepatide in adults with overweight/obesity and risk for developing T2D.

Younger US veterans with PTSD and type 2 diabetes who no longer met criteria for PTSD were less likely to initiate insulin and had reduced odds of mortality.

The medical experts conclude by summarizing essential insights and practical tips for effectively managing diabetes in elderly patients.

Medical professionals evaluate strategies for optimizing diabetes treatment protocols in older adults, emphasizing the critical role of deprescribing in geriatric diabetes care.

Diabetes specialists examine the shifting paradigm of type 2 diabetes treatment, highlighting the role of combination therapies and emerging approaches specifically designed for geriatric patients.

The panel examines crucial factors in determining appropriate medication dosages and managing glucose levels for elderly patients with type 2 diabetes.

Medical experts analyze a case involving a 78-year-old man with a 15-year history of Type 2 Diabetes Mellitus.

A panel of medical experts presents a case study featuring a 68-year-old woman exhibiting classic diabetes symptoms—polyuria, polydipsia, and significant weight loss—along with a notably elevated glucose level of 458 mg/dL.

Medical doctors examine strategies for customizing diabetes care for older adults across various environments, from home settings to healthcare facilities.

In a head-to-head real world study, tirzepatide compared with semaglutide resulted in 42%, 20%, and 46% reduced risks for all-cause mortality and major adverse CV and renal events, respectively.

Medical experts explore personalized diabetes management strategies, emphasizing the critical need to tailor treatments for older adults.

Caissa Troutman, MD, discusses how clinicians can tailor management plans to reduce risk of developing T2D in patients with obesity.

Hypoglycemia unawareness increased over time with use of sulfonylureas but decreased with use of insulin over the same period, a new study found.

Your daily dose of the clinical news you may have missed.

The oral GLP-1 RA was associated with weight loss of 7.3% in just 4 weeks and is designed with unique properties that will enhance multiple outcomes, Roche said.